This appraisal is to be rescheduled to allow the company (Pfizer) additional time to resolve unforeseen issues with their economic modelling. This delay means that this appraisal will be removed from the NICE’s reporting targets for timeliness. In addition, through this request for delay the company accepts that this drug will not be eligible to receive interim CDF funding from the date of marketing authorization.